Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Colorcon

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,183,006


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,183,006
Title:Methods of therapeutic monitoring of nitrogen scavenging drugs
Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
Inventor(s): Scharschmidt; Bruce (San Francisco, CA), Mokhtarani; Masoud (Walnut Creek, CA)
Assignee: Horizon Therapeutics, LLC (Lake Forest, IL)
Application Number:15/980,376
Patent Claims: 1. A method of treating a urea cycle disorder (UCD) in a subject in need thereof who has hepatic impairment wherein the hepatic impairment is of class B or C according to the Child-Pugh Score, the method comprising: administering a nitrogen scavenging agent to the subject at a dosage of 5 g/m.sup.2/day, wherein the nitrogen scavenging agent is glyceryl tri-[4-phenylbutyrate].

2. The method of claim 1, further comprising administering an increased dosage of the nitrogen scavenging agent to the subject wherein the increased dosage is calculated based on a target nitrogen output.

3. The method of claim 1, further comprising administering an increased dosage of the nitrogen scavenging agent to the subject wherein the increased dosage is calculated based on urinary PAGN level.

4. The method of claim 1, further comprising administering an increased dosage of the nitrogen scavenging agent to the subject wherein the increased dosage is calculated based on the subject's urinary PAGN level in combination with the subject's ammonia level.

5. The method of claim 1, further comprising administering an increased dosage of the nitrogen scavenging agent to the subject wherein the increased dosage is calculated based on the ratio of the concentration of urinary PAGN to urinary creatinine.

6. The method of claim 1, further comprising administering an increased dosage of the nitrogen scavenging agent to the subject, if the subject's fasting blood ammonia level is greater than half the upper limit of normal for the laboratory which performed the fasting blood ammonia level measurement.

7. The method of claim 1, wherein the nitrogen scavenging agent is administered orally.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Moodys
Dow
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.